About

Aims

The center aims to meet scientific challenges in issues of critical importance in the development and evaluation of FDA-regulated products and at a time of rapid technological progress by:

  • Advancing regulatory science through the development and application of quantitative and systems-level methodologies.
  • Creating a West Coast presence of the FDA to enhance communication between academia and the pharmaceutical, biotechnology, and high–tech industries, with the FDA, about regulatory science.

Focus areas

The UCSF-Stanford CERSI builds on the enormous strengths of UCSF and Stanford University in the biomedical, quantitative sciences, and pharmacology to provide novel collaborative research and educational programs that focus on three key FDA priority areas as described in FDA's Regulatory Science Framework:

  • Modernize development and evaluation of FDA-regulated products

    1. Alternative Methods
    2. Advanced Manufacturing Approaches
    3. Analytical and Computational Methods
    4. Biomarkers
    5. Clinical Outcome Assessment
    6. Complex and Novel Clinical Trial Design
    7. Predictive Toxicology
    8. Methods for Assessing Behavioral, Economic, or Human Factors
    9. Approaches to Incorporate Patient and Consumer Input
    10. Methods to Assess Real-World Data to serve as Real-World Evidence
    11. Methods to Assess Data Source Interoperability
  • Strengthen post-market surveillance and labeling of FDA-regulated products

    1. Methods to Assess Real-World Data to Support Regulatory Decision-Making
    2. Using and Validating Artificial Intelligence Approaches
    3. Novel Clinical Trial Design, Statistical and Epidemiologic Methods
    4. Automated Reporting Tools for Adverse Events and Active Surveillance
    5. Methods to Improve Communication About Risk to Patients and Consumers
    6. Approach to Expand Data Capacity, and Increase Data Quality and Usen
    7. Efforts to Harmonize Existing and Emerging Data Standards
  • Invigorate public health preparedness and response of FDA, patients & consumers

    1. Reinforce Medical countermeasures Initiative (MCMi)
    2. Antimicrobial Resistance
    3. Patient and Consumer Engagement
    4. Substance Use and Misuse
    5. One Health Approaches
    6. Global Product Safety net
    7. Emerging Technologies

Collaboration: interdisciplinary and multidisciplinary

The UCSF-Stanford CERSI is the first regulatory science center on the West Coast. Due to its unique geographic location and proximity to the San Francisco Bay Area pharmaceutical, biotechnology, and high-tech industries it naturally creates a liaison among the FDA, academia, and industry, supporting a collaborative environment within—as well as beyond—the two institutions.

The center is uniquely positioned to foster strong interdisciplinary and multidisciplinary collaborations through its diverse array of schools, departments, and institutes. Both universities bring their individual academic and research strengths to the center.

UCSF

FDA CERSI Lecture Series

Lectures are presented by scientists from CERSI Academic Institutions

FDA CERSI Workshops

Workshops are held collaboratively between FDA and CERSI Academic Institutions

Have questions?

Still have questions about the CERSI collaboration and research.

Email us with your questions

Beginnings

The UCSF-Stanford CERSI was launched in April 2014. 

See the public announcement